Table 2.

Hemodynamic Values Measured in the Upright Position at Rest and During Exercise Before and After 12 Weeks of Treatment With Sildenafil or Placebo

	Placebo				Sildenafil
	Baseline Rest	Week 12 Rest	Baseline Exercise	Week 12 Exercise	Baseline Rest	Week 12 Rest	Baseline Exercise	Week 12 Exercise
Heart rate, min −1	70 ± 7	73 ± 14	103 ± 11	105 ± 25	74 ± 11	78 ± 14	112 ± 17	120 ± 22
MAP, mm Hg	84 ± 14	82 ± 11	98 ± 15	94 ± 22	76 ± 22	78 ± 22	87 ± 11	91 ± 11
Right atrial pressure, mm Hg	8 ± 7	7 ± 4	16 ± 7	16 ± 7	6 ± 4	6 ± 4	16 ± 7	16 ± 7
Mean PAP, mm Hg	33 ± 11	31 ± 11	50 ± 11	50 ± 14	30 ± 7	28 ± 7	48 ± 7	45 ± 7
PCWP, mm Hg	19 ± 7	19 ± 7	30 ± 7	30 ± 7	18 ± 7	18 ± 7	28 ± 7	28 ± 7
PVR, dyne/s per cm −5	360 ± 290	340 ± 05	300 ± 160	320 ± 194	340 ± 142	280 ± 146*	250 ± 110	180 ± 58*
SVR, dyne/s per cm −5	1930 ± 900	2020 ± 790	1190 ± 370	1160 ± 470	2130 ± 710	2020 ± 630	850 ± 170	770 ± 172
LV ejection fraction, %	28 ± 4	28 ± 7	32 ± 7	32 ± 7	26 ± 4	27 ± 7	28 ± 4	28 ± 7
RV ejection fraction, %	35 ± 7	37 ± 11	34 ± 7	37 ± 11	33 ± 11	37 ± 11	34 ± 11	35 ± 11
Peak VO2, mL/kg per min			10.2 ± 2.8	9.9 ± 3.2			12.2 ± 2.3	13.9 ± 3.6*
VE/VCO2 slope			40.6 ± 9.6	41.4 ± 14.0			45.6 ± 10.7	41.6 ± 8.9
VD/VT	0.46 ± 0.04	0.48 ± 0.04	0.39 ± 0.07	0.41 ± 0.07	0.46 ± 0.07	0.44 ± 0.07	0.39 ± 0.11	0.37 ± 0.07
pH	7.46 ± 0.04	7.46 ± 0.04	7.45 ± 0.04	7.45 ± 0.04	7.45 ± 0.04	7.45 ± 0.04	7.45 ± 0.04	7.43 ± 0.04
PaO2, mm Hg	89 ± 14	93 ± 14	92 ± 14	89 ± 11	94 ± 14	92 ± 11	93 ± 24	87 ± 18
PaCO2, mm Hg	38 ± 7	39 ± 7	36 ± 7	37 ± 7	37 ± 4	36 ± 4	34 ± 4	33 ± 4
C(a–v)O2, mL O2/dL	8.88 ± 2.11	9.23 ± 2.10	13.9 ± 2.9	13.5 ± 2.4	8.47 ± 2.4	7.67 ± 1.4	14.5 ± 2.9	13.6 ± 2.9

Data are presented as mean±SD. MAP indicates mean arterial pressure; PAP, pulmonary arterial pressures; C(a–v)O₂, difference in oxygen content between arterial and venous blood.

^*P<0.05 for comparison of baseline with week 12 measurements between groups by 1-way ANOVA.